Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U.
Shumilov E, et al. Among authors: bacher u.
Leuk Lymphoma. 2016 Oct;57(10):2476-80. doi: 10.3109/10428194.2016.1151510. Epub 2016 Feb 25.
Leuk Lymphoma. 2016.
PMID: 26916814
No abstract available.